Comparison Between Clinicopathological Characteristics, BRAF V600E and TERT Promoter Mutation of Familial Non-Medullary Thyroid Carcinomas, and Sporadic Case

被引:1
作者
Yang, Tian [1 ,2 ]
Huang, Longsheng [1 ,2 ]
Chen, Chang [1 ]
Luo, Han [3 ]
Jiang, Yong [1 ]
机构
[1] Sichuan Univ, Dept Pathol, West China Hosp, Chengdu, Peoples R China
[2] Sichuan Univ, West China Sch Med, Chengdu, Peoples R China
[3] Sichuan Univ, Thyroid & Parathyroid Surg Ctr, West China Hosp, Chengdu, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2021年 / 11卷
关键词
familial non-medullary thyroid carcinomas; clinicopathological characteristics; BRAF V600E; TERT promoter; papillary thyroid cancer; HASHIMOTOS-THYROIDITIS; PAPILLARY; PROGNOSIS; CANCER; ASSOCIATION; FEATURES;
D O I
10.3389/fonc.2021.616974
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundIt has been debated whether familial non-medullary thyroid carcinoma (FNMTC) is more aggressive and has a worse prognosis than sporadic non-medullary thyroid carcinoma (SNMTC). Our aim was to compare the invasiveness and prognosis of FNMTC and SNMTC by their biological behavior and molecular changes. Method and MaterialOur group mainly compared 106 patients with FNMTC whom have complete clinicopathological data during 2011-2019 in West China Hospital, Sichuan University, and 212 randomly selected cases with SNMTC were included to compare their biological behavior, recurrence and mortality, and molecular expression of BRAF V600E and TERT promoter. At the same time, FNMTC cases were divided into four subgroups, namely, two affected members group, three or more affected members, parent/offspring group, and sibling group, and they were compared with SNMTC separately to analyze the difference in their invasiveness and prognosis. ResultsWe found that the mean tumor size of FNMTC (0.96 +/- 0.53cm) was smaller than that of SNMTC (1.15 +/- 0.72 cm) (p = 0.020), while no significant difference in the incidence of other clinicopathological factors, including bilateral growth, capsular invasion, with thyroid nodular goiter or not, multifocality, lymph node metastasis, extrathyroidal extension, iodine 131 treatments, T stage, and American Joint Committee on Cancer (AJCC) stage, was observed between FNMTC and SNMTC (p > 0.05), between each FNMTC subgroup (p > 0.05), and between each FNMTC subgroup and SNMTC (p > 0.05). There was no significant difference in recurrence, mortality, and BRAF V600E and TERT promoter mutation between FNMTC and SNMTC, among which 50/60 (83.33%) of FNMTC patients had BRAF V600E mutation and 1/32 (3.13%) had TERT promoter mutation, while the mutation rates of SNMTC were 93/108 (86.11%) and 3/64 (4.69%) (p > 0.05). ConclusionThere was no significant difference in invasiveness and prognosis between FNMTC and SNMTC by biological behavior, patient survival, and molecular level comparison.
引用
收藏
页数:9
相关论文
共 30 条
  • [1] Integrated Genomic Characterization of Papillary Thyroid Carcinoma
    Agrawal, Nishant
    Akbani, Rehan
    Aksoy, B. Arman
    Ally, Adrian
    Arachchi, Harindra
    Asa, Sylvia L.
    Auman, J. Todd
    Balasundaram, Miruna
    Balu, Saianand
    Baylin, Stephen B.
    Behera, Madhusmita
    Bernard, Brady
    Beroukhim, Rameen
    Bishop, Justin A.
    Black, Aaron D.
    Bodenheimer, Tom
    Boice, Lori
    Bootwalla, Moiz S.
    Bowen, Jay
    Bowlby, Reanne
    Bristow, Christopher A.
    Brookens, Robin
    Brooks, Denise
    Bryant, Robert
    Buda, Elizabeth
    Butterfield, Yaron S. N.
    Carling, Tobias
    Carlsen, Rebecca
    Carter, Scott L.
    Carty, Sally E.
    Chan, Timothy A.
    Chen, Amy Y.
    Cherniack, Andrew D.
    Cheung, Dorothy
    Chin, Lynda
    Cho, Juok
    Chu, Andy
    Chuah, Eric
    Cibulskis, Kristian
    Ciriello, Giovanni
    Clarke, Amanda
    Clayman, Gary L.
    Cope, Leslie
    Copland, John A.
    Covington, Kyle
    Danilova, Ludmila
    Davidsen, Tanja
    Demchok, John A.
    DiCara, Daniel
    Dhalla, Noreen
    [J]. CELL, 2014, 159 (03) : 676 - 690
  • [2] TERT Promoter Mutations in Thyroid Cancer
    Alzahrani, Ali S.
    Alsaadi, Rawan
    Murugan, Avaniyapuram Kannan
    Bin Sadiq, Bakr
    [J]. HORMONES & CANCER, 2016, 7 (03): : 165 - 177
  • [3] An update on familial nonmedullary thyroid cancer
    Ammar, Sabrine A.
    Alobuia, Wilson M.
    Kebebew, Electron
    [J]. ENDOCRINE, 2020, 68 (03) : 502 - 507
  • [4] Association of Hashimoto's thyroiditis with thyroid cancer
    Azizi, G.
    Keller, J. M.
    Lewis, M.
    Piper, K.
    Puett, D.
    Rivenbark, K. M.
    Malchoff, C. D.
    [J]. ENDOCRINE-RELATED CANCER, 2014, 21 (06) : 845 - 852
  • [5] Clinicopathological features and prognosis of familial papillary thyroid carcinoma - a large-scale, matched, case-control study
    Cao, Jun
    Chen, Can
    Chen, Chao
    Wang, Qing-Liang
    Ge, Ming-Hua
    [J]. CLINICAL ENDOCRINOLOGY, 2016, 84 (04) : 598 - 606
  • [6] Fine Needle Aspiration in the Investigation of Thyroid Nodules Indications, Procedures and Interpretation
    Feldkamp, Joachim
    Fuehrer, Dagmar
    Luster, Markus
    Musholt, Thomas J.
    Spitzweg, Christine
    Schott, Matthias
    [J]. DEUTSCHES ARZTEBLATT INTERNATIONAL, 2016, 113 (20): : 353 - +
  • [7] Hereditary and familial thyroid tumours
    Guilmette, Julie
    Nose, Vania
    [J]. HISTOPATHOLOGY, 2018, 72 (01) : 70 - 81
  • [8] Biological behavior and prognosis of familial papillary thyroid carcinoma
    Ito, Yasuhiro
    Kakudo, Kennichi
    Hirokawa, Mitsuyoshi
    Fukushima, Mitsuhiro
    Yabuta, Tomonori
    Tomoda, Chisato
    Inoue, Hiroyuki
    Kihara, Minoru
    Higashiyama, Takuya
    Uruno, Takashi
    Takamura, Yuuki
    Miya, Akihiro
    Kobayashi, Kaoru
    Matsuzuka, Fumio
    Miyauchi, Akira
    [J]. SURGERY, 2009, 145 (01) : 100 - 105
  • [9] Jemal A, 2011, CA-CANCER J CLIN, V61, P134, DOI [10.3322/caac.21492, 10.3322/caac.20115, 10.3322/caac.20107]
  • [10] BRAF and TERT promoter mutations in the aggressiveness of papillary thyroid carcinoma: a study of 653 patients
    Jin, Langping
    Chen, Endong
    Dong, Siyang
    Cai, Yefeng
    Zhang, Xiangjian
    Zhou, Yili
    Zeng, Ruichao
    Yang, Fan
    Pan, Chuanmeng
    Liu, Yehuan
    Wu, Weili
    Xing, Mingzhao
    Zhang, Xiaohua
    Wang, Ouchen
    [J]. ONCOTARGET, 2016, 7 (14) : 18346 - 18355